Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).

Kinase inhibitors are the largest class of new cancer drugs. However, it is already apparent that most tumours can escape from the inhibition of any single kinase. If it is necessary to inhibit ...

Brukinsa won approval for another blood cancer last month. ArQule's lead product candidate is a BTK inhibitor, ARQ-531, designed for heavily pretreated patients with leukemias and lymphomas ...

The BTK inhibitors market has experienced significant dynamics driven by advancements in oncology and autoimmune disease treatments. One of the primary drivers of the BTK inhibitors market is the ...

Sanofi has paused recruitment in its international phase 3 trials of BTK inhibitor tolebrutinib for multiple sclerosis, although it says studies aimed at getting US approval are on track to ...

Roche has presented more data from a Phase II study of its Bruton’s tyrosine kinase (BTK) inhibitor after long-term data ...

Jaypirca belongs to a class of medications called Bruton’s tyrosine kinase (BTK) inhibitors, which block a protein critical ...

Furthest ahead in the pipeline is tolebrutinib, developed by Paris-based Sanofi to potentially treat SPMS, PPMS and relapsing forms of MS. The investigational agent is an oral central nervous system ...

Extrapolating from these trends, it is plausible that some drug discovery programmes in the near future will profile every kinase inhibitor that is synthesized against most of the kinome.